Title: Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337.
2055048-57-0
1834515-99-9
2055042-82-3
2100306-63-4 | N-(Boc-peg1)-n-bis(peg2-propargyl) | AA019E9B | MFCD30723238
2183440-29-9 | N-(t-butyl ester-PEG3)-N-bis(PEG3-amine) | AA019EE1 | MFCD31561124
1297537-37-1 | 2-Chloro-4-(1H-pyrazol-5-yl)benzonitrile | AA019EHV | MFCD28365702
225122-33-8 | tert-Butyl (1-((cyanomethyl)carbamoyl)cyclohexyl)carbamate | AA019EKZ | MFCD24392169
959466-51-4 | 2,4-bis(phenylmethoxy)-5-propan-2-ylbenzaldehyde | AA019ENS | MFCD24849960
107208-70-8 | 2-bromo-2-chloro-1,1-biphenyl | AA019EQZ | MFCD00466291
58826-39-4 | 6-Chloro-7-methyl-[1,2,4]triazolo[4,3-b]pyridazine | AA019ETZ | MFCD04037382
1554658-43-3 | 4-Chloro-3-fluoro-2-methoxybenzaldehyde | AA019EXF | MFCD24686301
91456-35-8 | Benzene, 1-chloro-3-isocyanato-5-methyl- | AA019FOV | MFCD00060317
1932784-54-7 | (2S,5S)-Fmoc-5-methylpyrrolidine-2-carboxylic acid | AA019FXT | MFCD28385804
